San Diegos Acadia Awaits Parkinsons Trial Results (and a Chance to Prove Naysayers Wrong)
Summary
Just a couple of weeks ago, the life sciences startup got a strong vote of confidence from Canada’s Biovail, which paid $30 million upfront as part of a deal to develop a promising drug now in clinical tests for psychosis related to Parkinson’s disease.Wall Street has assigned Acadia a market value of about $65 million, just a tad north of its total cash on hand.That’s when the company expects to see the results of a late-stage trial for pimavanserin, Acadia’s drug candidate for Parkinson’s disease-related psychosis.An estimated 1.5 million Americans have Parkinson’s disease, and as many as 40 percent of them experience hallucinations or delusions, although the severity varies.Although many patients receive antipsychotic drugs, a 2006 federal study found the medications were risky to … Next Page »